Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol

Advances in Nutrition

Volumn 2, Issue 3, 2011, Pages 261-274

  Flock, Michael R ^a   Green, Michael H ^a   Kris Etherton, Penny M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; HORMONE; LOW DENSITY LIPOPROTEIN RECEPTOR;

ADIPOSE TISSUE; BLOOD; CHOLESTEROL INTAKE; DIET THERAPY; FAT INTAKE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; METABOLISM; MICROBIOLOGY; OBESITY; REVIEW;

ADIPOSE TISSUE; ADIPOSITY; CHOLESTEROL, DIETARY; DIETARY FATS; FATTY ACIDS; HORMONES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTESTINES; LIPID METABOLISM; LIVER; METABOLIC SYNDROME X; OBESITY; RECEPTORS, LDL;

EID: 84860459972     PISSN: 21618313     EISSN: 21565376     Source Type: Journal    
DOI: 10.3945/an.111.000422     Document Type: Review

References (121)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735-52.
2. Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism. 1980; 29: 1053-60.
3. Keys A, Aravanis C, Blackburn H, Van Buchem FS, Buzina R, Djordjevic BS, Fidanza F, Karvonen MJ, Menotti A, et al. Coronary heart disease: overweight and obesity as risk factors. Ann Intern Med. 1972; 77: 15-27.
4. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003; 163: 427-36.
5. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008; 28: 629-36.
6. Boerwinkle E, Brown SA, Rohrbach K, Gotto AM Jr, PatschW. Role of apolipoprotein E and B gene variation in determining response of lipid, lipoprotein, and apolipoprotein levels to increased dietary cholesterol. Am J Hum Genet. 1991; 49: 1145-54.
7. Tikkanen MJ, Xu CF, Hamalainen T, Talmud P, Sarna S, Huttunen JK, Pietinen P, Humphries S. XbaI polymorphism of the apolipoprotein B gene influences plasma lipid response to diet intervention. Clin Genet. 1990; 37: 327-34.
8. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest. 2008; 118: 2992-3002.
9. Lefevre M, Champagne CM, Tulley RT, Rood JC, Most MM. Individual variability in cardiovascular disease risk factor responses to low-fat and low-saturated-fat diets in men: body mass index, adiposity, and insulin resistance predict changes in LDL cholesterol. Am J Clin Nutr. 2005; 82: 957-63.
10. Gylling H, Miettinen TA. Cholesterol absorption, synthesis, and LDL metabolism in NIDDM. Diabetes Care. 1997; 20: 90-5.
11. Berglund L, Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Dennis BH, et al. Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr. 2007; 86: 1611-20.
12. Lichtenstein AH, Matthan NR, Jalbert SM, Resteghini NA, Schaefer EJ, Ausman LM. Novel soybean oils with different fatty acid profiles alter cardiovascular disease risk factors in moderately hyperlipidemic subjects. Am J Clin Nutr. 2006; 84: 497-504.
13. USDA. Dietary Guidelines for Americans, 2010 [cited 2011 Feb 2]. Available from: http://www.health.gov/dietaryguidelines/dga2010/DietaryGuidelines2010.pdf.
14. Mustad VA, Etherton TD, Cooper AD, Mastro AM, Pearson TA, Jonnalagadda SS, Kris-Etherton PM. Reducing saturated fat intake is associated with increased levels of LDL receptors on mononuclear cells in healthy men and women. J Lipid Res. 1997; 38: 459-68.
15. Cole TG, Bowen PE, Schmeisser D, Prewitt TE, Aye P, Langenberg P, Dolecek TA, Brace LD, Kamath S. Differential reduction of plasma cholesterol by the American Heart Association Phase 3 Diet in moderately hypercholesterolemic, premenopausal women with different body mass indexes. Am J Clin Nutr. 1992; 55: 385-94.
16. Hannah JS, Jablonski KA, Howard BV. The relationship between weight and response to cholesterol-lowering diets in women. Int J Obes Relat Metab Disord. 1997; 21: 445-50.
17. Jansen S, Lopez-Miranda J, Salas J, Castro P, Paniagua JA, Lopez-Segura F, Ordovas JM, Jimenez-Pereperez JA, Blanco A, et al. Plasma lipid response to hypolipidemic diets in young healthy non-obese men varies with body mass index. J Nutr. 1998; 128: 1144-9.
18. Bronsgeest-Schoute DC, Hermus RJ, Dallinga-Thie GM, Hautvast JG. Dependence of the effects of dietary cholesterol and experimental conditions on serum lipids in man. III. The effect on serum cholesterol of removal of eggs from the diet of free-living habitually eggeating people. Am J Clin Nutr. 1979; 32: 2193-7.
19. Denke MA, Adams-Huet B, Nguyen AT. Individual cholesterol variation in response to a margarine-or butter-based diet: A study in families. JAMA. 2000; 284: 2740-7.
20. Knopp RH, Retzlaff B, Fish B, Walden C, Wallick S, Anderson M, Aikawa K, Kahn SE. Effects of insulin resistance and obesity on lipoproteins and sensitivity to egg feeding. Arterioscler Thromb Vasc Biol. 2003; 23: 1437-43.
21. Nabeno-Kaeriyama Y, Fukuchi Y, Hayashi S, Kimura T, Tanaka A, Naito M. Delayed postprandial metabolism of triglyceride-rich lipoproteins in obese young men compared to lean young men. Clin Chim Acta. 2010; 411: 1694-9.
22. Oh SY, Miller LT. Effect of dietary egg on variability of plasma cholesterol levels and lipoprotein cholesterol. Am J Clin Nutr. 1985; 42: 421-31.
23. Katan MB, Beynen AC. Characteristics of human hypo-and hyperresponders to dietary cholesterol. Am J Epidemiol. 1987; 125: 387-99.
24. Cox C, Mann J, Sutherland W, Ball M. Individual variation in plasma cholesterol response to dietary saturated fat. BMJ. 1995; 311: 1260-4.
25. Clifton PM, Abbey M, Noakes M, Beltrame S, Rumbelow N, Nestel PJ. Body fat distribution is a determinant of the high-density lipoprotein response to dietary fat and cholesterol in women. Arterioscler Thromb Vasc Biol. 1995; 15: 1070-8.
26. Sabate J, Oda K, Ros E. Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials. Arch Intern Med. 2010; 170: 821-7.
27. Griel AE, Kris-Etherton PM. Tree nuts and the lipid profile: a review of clinical studies. Br J Nutr. 2006; 96 Suppl 2: S68-78.
28. Mukuddem-Petersen J, Oosthuizen W, Jerling JC. A systematic review of the effects of nuts on blood lipid profiles in humans. J Nutr. 2005; 135: 2082-9.
29. Mukuddem-Petersen J, Stonehouse Oosthuizen W, Jerling JC, Hanekom SM, White Z. Effects of a high walnut and high cashew nut diet on selected markers of the metabolic syndrome: a controlled feeding trial. Br J Nutr. 2007; 97: 1144-53.
30. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303: 235-41.
31. Erlinger TP, Miller ER III, Charleston J, Appel LJ. Inflammation modifies the effects of a reduced-fat low-cholesterol diet on lipids: results from the DASH-sodium trial. Circulation. 2003; 108: 150-4.
32. Hilpert KF, Kris-Etherton PM, West SG. Lipid response to a low-fat diet with or without soy is modified by C-reactive protein status in moderately hypercholesterolemic adults. J Nutr. 2005; 135: 1075-9.
33. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282: 2131-5.
34. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr. 2008; 32: 638-44.
35. Mekki N, Christofilis MA, Charbonnier M, Atlan-Gepner C, Defoort C, Juhel C, Borel P, Portugal H, Pauli AM, et al. Influence of obesity and body fat distribution on postprandial lipemia and triglyceriderich lipoproteins in adult women. J Clin Endocrinol Metab. 1999; 84: 184-91.
36. Dallongeville J, Gruson E, Dallinga-Thie G, Pigeyre M, Gomila S, Romon M. Effect of weight loss on the postprandial response to high-fat and high-carbohydrate meals in obese women. Eur J Clin Nutr. 2007; 61: 711-8.
37. James AP, Watts GF, Barrett PH, Smith D, Pal S, Chan DC, Mamo JC. Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. Metabolism. 2003; 52: 136-41.
38. Simonen P, Gylling H, Howard AN, Miettinen TA. Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr. 2000; 72: 82-8.
39. Volek JS, Sharman MJ, Gomez AL, DiPasquale C, Roti M, Pumerantz A, Kraemer WJ. Comparison of a very low-carbohydrate and low-fat diet on fasting lipids, LDL subclasses, insulin resistance, and postprandial lipemic responses in overweight women. J Am Coll Nutr. 2004; 23: 177-84.
40. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-9.
41. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002; 106: 3143-421.
42. Wideman L, Kaminsky LA, Whaley MH. Postprandial lipemia in obese men with abdominal fat patterning. J Sports Med Phys Fitness. 1996; 36: 204-10.
43. Katan MB. The response of lipoproteins to dietary fat and cholesterol in lean and obese persons. Curr Cardiol Rep. 2006; 8: 446-51.
44. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997; 89: 331-40.
45. Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in the diet. IV. Particular saturated fatty acids in the diet. Metabolism. 1965; 14: 776-87.
46. Björkhem I. Do oxysterols control cholesterol homeostasis? J Clin Invest. 2002; 110: 725-30.
47. Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K, Beltowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw (Online). 2007; 61: 736-59.
48. Goodwin B, Watson MA, Kim H, Miao J, Kemper JK, Kliewer SA. Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver x receptor-alpha. Mol Endocrinol. 2003; 17: 386-94.
49. Rudel L, Deckelman C, Wilson M, Scobey M, Anderson R. Dietary cholesterol and downregulation of cholesterol 7 alpha-hydroxylase and cholesterol absorption in African green monkeys. J Clin Invest. 1994; 93: 2463-72.
50. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109: 1125-31.
51. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes. 2007; 56: 901-11.
52. Wang B, Wood IS, Trayhurn P. Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch. 2007; 455: 479-92.
53. Wang P, Mariman E, Renes J, Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol. 2008; 216: 3-13.
54. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007; 132: 2169-80.
55. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006; 116: 3015-25.
56. Kanneganti T-D, Lamkanfi M, Núñez G. Intracellular NOD-like receptors in host defense and disease. Immunity. 2007; 27: 549-59.
57. Vandanmagsar B, Youm Y-H, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM, Dixit VD. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011; 17: 179-88
58. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett. 2008; 582: 97-105.
59. Stephens JM, Lee J, Pilch PF. Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J Biol Chem. 1997; 272: 971-6.
60. Ruan H, Hacohen N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes. 2002; 51: 1319-36.
61. Roytblat L, Rachinsky M, Fisher A, Greemberg L, Shapira Y, Douvdevani A, Gelman S. Raised interleukin-6 levels in obese patients. Obes Res. 2000; 8: 673-5.
62. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994; 43: 1271-8.
63. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95: 2409-15.
64. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res. 2000; 49: 497-505.
65. Das UN. Metabolic syndrome pathophysiology: the role of essential fatty acids. Singapore: Wiley-Blackwell; 2010.
66. Lam TK, Pocai A, Gutierrez-Juarez R, Obici S, Bryan J, Aguilar-Bryan L, Schwartz GJ, Rossetti L. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med. 2005; 11: 320-7.
67. Obici S, Feng Z, Morgan K, Stein D, Karkanias G, Rossetti L. Central administration of oleic acid inhibits glucose production and food intake. Diabetes. 2002; 51: 271-5.
68. McGillicuddy FC, de la LleraMoyaM, Hinkle CC, JoshiMR, Chiquoine EH, Billheimer JT, Rothblat GH, Reilly MP. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009; 119: 1135-45.
69. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002; 23: 201-29.
70. Tobin KA, Ulven SM, Schuster GU, Steineger HH, Andresen SM, Gustafsson JA, Nebb HI. Liver X receptors as insulin-mediating factors in fatty acid and cholesterol biosynthesis. J Biol Chem. 2002; 277: 10691-7.
71. Yu L, York J, von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J Biol Chem. 2003; 278: 15565-70.
72. Pihlajamaki J, Gylling H, Miettinen TA, Laakso M. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res. 2004; 45: 507-12.
73. Tsubakio-Yamamoto K, Nishida M, Nakagawa-Toyama Y, Masuda D, Ohama T, Yamashita S. Current therapy for patients with sitosterolemia-effect of ezetimibe on plant sterol metabolism. J Atheroscler Thromb. 2010; 17: 891-900.
74. Klett EL, Lee MH, Adams DB, Chavin KD, Patel SB. Localization of ABCG5 and ABCG8 proteins in human liver, gall bladder and intestine. BMC Gastroenterol. 2004; 4: 21.
75. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000; 290: 1771-5
76. van der Velde AE, Vrins CL, van den Oever K, Seemann I, Oude Elferink RP, van Eck M, Kuipers F, Groen AK. Regulation of direct transintestinal cholesterol excretion in mice. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G203-8.
77. Zhao HL, Houweling AH, Vanstone CA, Jew S, Trautwein EA, Duchateau GS, Jones PJ. Genetic variation in ABC G5/G8 and NPC1L1 impact cholesterol response to plant sterols in hypercholesterolemic men. Lipids. 2008; 43: 1155-64.
78. Santosa S, Demonty I, Lichtenstein AH, Ordovas JM, Jones PJ. Single nucleotide polymorphisms in ABCG5 and ABCG8 are associated with changes in cholesterol metabolism during weight loss. J Lipid Res. 2007; 48: 2607-13.
79. Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in human liver cells. Hepatology. 2006; 43: 1202-10.
80. Li T, Ma H, Chiang JYL. TGFb1, TNFa, and insulin signaling crosstalk in regulation of the rat cholesterol 7a-hydroxylase gene expression. J Lipid Res. 2008; 49: 1981-9.
81. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004; 303: 1201-4.
82. Cohen JC, Pertsemlidis A, Fahmi S, Esmail S, Vega GL, Grundy SM, Hobbs HH. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci USA. 2006; 103: 1810-5.
83. Davis HR Jr, Altmann SW. Niemann-Pick C1 Like 1 (NPC1L1) an intestinal sterol transporter. Biochim Biophys Acta. 2009; 1791: 679-83.
84. Ahmed MH, Byrne CD. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Diabetes Obes Metab. 2010; 12: 958-66.
85. Labonte ED, Camarota LM, Rojas JC, Jandacek RJ, Gilham DE, Davies JP, Ioannou YA, Tso P, Hui DY, et al. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l12/2 mice. Am J Physiol Gastrointest Liver Physiol. 2008; 295: G776-83.
86. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007; 581: 5664-70.
87. Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepatic Neiman-Pick C1-Like 1 improves hepatic insulin resistance. Am J Physiol Endocrinol Metab. Epub 2009 Aug 4.
88. Picard F, Boivin A, Lalonde J, Deshaies Y. Resistance of adipose tissue lipoprotein lipase to insulin action in rats fed an obesity-promoting diet. Am J Physiol Endocrinol Metab. 2002; 282: E412-8.
89. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002; 43: 1363-79.
90. Griffin BA. Lipoprotein atherogenicity: an overview of current mechanisms. Proc Nutr Soc. 1999; 58: 163-9.
91. Stoeckel LE, Weller RE, Cook EW III, Twieg DB, Knowlton RC, Cox JE. Widespread reward-system activation in obese women in response to pictures of high-calorie foods. Neuroimage. 2008; 41: 636-47.
92. Rothemund Y, Preuschhof C, Bohner G, Bauknecht HC, Klingebiel R, Flor H, Klapp BF. Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese individuals. Neuroimage. 2007; 37: 410-21.
93. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Müller-Wieland D, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000; 289: 2122-5.
94. Lind S, Rudling M, Ericsson S, Olivecrona H, Eriksson M, Borgstrom B, Eggertsen G, Berglund L, Angelin B. Growth hormone induces lowdensity lipoprotein clearance but not bile acid synthesis in humans. Arterioscler Thromb Vasc Biol. 2004; 24: 349-56.
95. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA. 1992; 89: 6983-7.
96. Rudling M, Angelin B. Loss of resistance to dietary cholesterol in the rat after hypophysectomy: importance of the presence of growth hormone for hepatic low density lipoprotein-receptor expression. Proc Natl Acad Sci USA. 1993; 90: 8851-5.
97. Galman C, Matasconi M, Persson L, Parini P, Angelin B, Rudling M. Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol. Am J Physiol Endocrinol Metab. 2007; 293: E737-42.
98. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord. 1999; 23: 260-71.
99. Parini P, Angelin B, Rudling M. Importance of estrogen receptors in hepatic LDL receptor regulation. Arterioscler Thromb Vasc Biol. 1997; 17: 1800-5.
100. Duan LP, Wang HH, Ohashi A, Wang DQ. Role of intestinal sterol transporters Abcg5, Abcg8, and Npc1l1 in cholesterol absorption in mice: gender and age effects. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G269-76.
101. Angelin B, Olivecrona H, Reihner E, Rudling M, Stahlberg D, Eriksson M, Ewerth S, Henriksson P, Einarsson K. Hepatic cholesterol metabolism in estrogen-treated men. Gastroenterology. 1992; 103: 1657-63.
102. Nyrnes A, Jorde R, Sundsfjord J. Serum TSH is positively associated with BMI. Int J Obes (Lond). 2005; 30: 100-5.
103. Knudsen N, Laurberg P, Rasmussen LB, Bulow I, Perrild H, Ovesen L, Jorgensen T. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab. 2005; 90: 4019-24.
104. Reinehr T, Isa A, de Sousa G, Dieffenbach R, Andler W. Thyroid hormones and their relation to weight status. Horm Res. 2008; 70: 51-7.
105. Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol. 2010; 316: 165-71.
106. Thompson GR, Soutar AK, Spengel FA, Jadhav A, Gavigan SJ, Myant NB. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc Natl Acad Sci USA. 1981; 78: 2591-5.
107. Bakker O, Hudig F, Meijssen S, Wiersinga WM. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem Biophys Res Commun. 1998; 249: 517-21.
108. Liberopoulos EN, Elisaf MS. Dyslipidemia in patients with thyroid disorders. Hormones (Athens). 2002; 1: 218-23.
109. Shin D-J, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2). J Biol Chem. 2003; 278: 34114-8.
110. Qi D, Rodrigues B. Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. Am J Physiol Endocrinol Metab. 2007; 292: E654-67.
111. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi M-C, Grino M. Expression of the mRNA coding for 11{beta}-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab. 2002; 87: 2701-5.
112. Rask E, Walker BR, Soderberg S, Livingstone DEW, Eliasson M, Johnson O, Andrew R, Olsson T. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11 {beta}-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab. 2002; 87: 3330-6.
113. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab. 1982; 54: 131-8.
114. Andrews RC, Herlihy O, Livingstone DEW, Andrew R, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab. 2002; 87: 5587-93.
115. Samuels MH. Effects of variations in physiological cortisol levels on thyrotropin secretion in subjects with adrenal insufficiency: a clinical research center study. J Clin Endocrinol Metab. 2000; 85: 1388-93.
116. DiBaise JK, Zhang H, Crowell MD, Krajmalnik-Brown R, Decker GA, Rittmann BE. Gut microbiota and its possible relationship with obesity. Mayo Clin Proc. 2008; 83: 460-9.
117. Bajzer M, Seeley RJ. Physiology: obesity and gut flora. Nature. 2006; 444: 1009-10.
118. Cronin J, Williams L, McAdam E, Eltahir Z, Griffiths P, Baxter J, Jenkins G. The role of secondary bile acids in neoplastic development in the oesophagus. Biochem Soc Trans. 2010; 38: 337-42.
119. Creely SJ, McTernan PG, Kusminski CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007; 292: E740-7.
120. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56: 1761-72.
121. Amar J, Burcelin R, Ruidavets JB, Cani PD, Fauvel J, Alessi MC, Chamontin B, Ferrieres J. Energy intake is associated with endotoxemia in apparently healthy men. Am J Clin Nutr. 2008; 87: 1219-23.